Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Almost 300 million people globally have chronic hepatitis B
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Subscribe To Our Newsletter & Stay Updated